Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatropin Therapy for Short Children Born of Premature Gestation
2004-004781-33Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of somatropin in growth disorder (2 arms), sponsored by Pfizer. Primary endpoints: Primary: Change in growth velocity SDS after one year and Primary: Change in height SDS after one year. Started May 2005; status: completed.
02
Drugs
somatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on 2004-004781-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004781-33.